Advocacy intelligence hub — real-time data for patient organizations
Sanofi — PHASE4
University of Edinburgh
Groupe français d'étude des Maladies Inflammatoires de loeil
Hôpital NOVO
Second Affiliated Hospital, School of Medicine, Zhejiang University — NA
Insel Gruppe AG, University Hospital Bern — PHASE3
University Hospital, Brest — PHASE3
National Institute of Allergy and Infectious Diseases (NIAID) — PHASE2
Vastra Gotaland Region
Rigshospitalet, Denmark
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Diclofenac Epolamine
IBSA
PIROXICAM
(PIROXICAM)standardUnichem Pharmaceuticals (USA), Inc.
Nonsteroidal Anti-inflammatory Drug [EPC]
12.1 Mechanism of Action Piroxicam has analgesic, anti-inflammatory, and antipyretic properties. The mechanism of action of piroxicam capsules, like t...
Actemra
(tocilizumab)Orphan drugstandardGenentech, Inc.
Interleukin-6 Receptor Antagonist [EPC]
12.1 Mechanism of Action Tocilizumab binds to both soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R), and has been shown to inhibit IL-6-m...
Peter A Merkel, MD, MPH
University of Pennsylvania
📍 Tampa, Florida
Peter A. Merkel, MD, MPH, MD, MPH
University of Pennsylvania
📍 RADNOR, PA
Laurence Bouillet, Professor
Grenoble Hospital University
📍 Grenoble
Divi CORNEC
CHRU de Brest - Service de rhumatologie
📍 Brest
Britta Maurer
Department of Rheumatology and Immunology, Inselspital, University of Bern, Bern, Switzerland
📍 WANTAGH, NY
Kenneth Warrington, MD, MD
Mayo Clinic
📍 ROCHESTER, MN